Galectin Therapeutics Inc. (GALT) Earnings History
Annual and quarterly earnings data from 2000 to 2024
Loading earnings history...
GALT EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
GALT Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
Download Data
Export GALT earnings history in CSV or JSON format
Free sign-in required to download data
Galectin Therapeutics Inc. (GALT) Earnings Overview
As of May 8, 2026, Galectin Therapeutics Inc. (GALT) reported trailing twelve-month net income of -$37M, reflecting -2.7% year-over-year growth. The company earned $-0.58 per diluted share over the past four quarters.
Looking at the long-term picture, GALT's historical earnings data spans multiple years. The company achieved its highest annual net income of -$190,000 in fiscal 2000.
Galectin Therapeutics Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including HALO ($317M net income, 22.7% margin), AKBA (-$21M net income, -2.3% margin), MDGL (-$309M net income, -30.1% margin), GALT has comparable earnings metrics. Compare GALT vs HALO →
GALT Earnings vs Peers
Earnings metrics vs comparable public companies
GALT Historical Earnings Data (2000–2024)
25 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$47M | -14.6% | -$42M | $-0.76 | - | - |
| 2023 | -$41M | -5.9% | -$38M | $-0.74 | - | - |
| 2022 | -$39M | -27.0% | -$38M | $-0.65 | - | - |
| 2021 | -$31M | -30.1% | -$30M | $-0.52 | - | - |
| 2020 | -$23M | -76.5% | -$23M | $-0.41 | - | - |
| 2019 | -$13M | +4.4% | -$13M | $-0.39 | - | - |
| 2018 | -$14M | +14.4% | -$14M | $-0.35 | - | - |
| 2017 | -$16M | +24.3% | -$16M | $-0.46 | - | - |
| 2016 | -$21M | -7.0% | -$21M | $-0.73 | - | - |
| 2015 | -$20M | -26.8% | -$20M | $-0.83 | - | - |
See GALT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs GALT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare GALT vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonGALT — Frequently Asked Questions
Quick answers to the most common questions about buying GALT stock.
Is GALT growing earnings?
GALT EPS of $-0.58 reflects slowing growth at -2.7%, below the 5-year CAGR of N/A. TTM net income is $-37M. Expansion rate has moderated.
What are GALT's profit margins?
Galectin Therapeutics Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are GALT's earnings?
GALT earnings data spans 2000-2024. The current earnings trend is -2.7% YoY. Historical data enables comparison across business cycles.